Literature DB >> 30946985

Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.

Nathan E Stone1, Amalee E Nunnally2, Victor Jimenez3, Emily K Cope4, Jason W Sahl5, Krystal Sheridan6, Heidie M Hornstra7, Jacob Vinocur8, Erik W Settles9, Kyle C Headley10, Charles H D Williamson11, Jai Ram Rideout12, Evan Bolyen13, J Gregory Caporaso14, Joel Terriquez15, Fernando P Monroy16, Joseph D Busch17, Paul Keim18, David M Wagner19.   

Abstract

Clostridioides difficile infection (CDI) is an emerging public health threat and C. difficile is the most common cause of antimicrobial-associated diarrhea worldwide and the leading cause of hospital-associated infections in the US, yet the burden of community-acquired infections (CAI) is poorly understood. Characterizing C. difficile isolated from canines is important for understanding the role that canines may play in CAI. In addition, several studies have suggested that canines carry toxigenic C. difficile asymptomatically, which may imply that there are mechanisms responsible for resistance to CDI in canines that could be exploited to help combat human CDI. To assess the virulence potential of canine-derived C. difficile, we tested whether toxins TcdA and TcdB (hereafter toxins) derived from a canine isolate were capable of causing tight junction disruptions to colonic epithelial cells. Additionally, we addressed whether major differences exist between human and canine cells regarding C. difficile pathogenicity by exposing them to identical toxins. We then examined the canine gut microbiome associated with C. difficile carriage using 16S rRNA gene sequencing and searched for deviations from homeostasis as an indicator of CDI. Finally, we queried 16S rRNA gene sequences for bacterial taxa that may be associated with resistance to CDI in canines. Clostridioides difficile isolated from a canine produced toxins that reduced tight junction integrity in both human and canine cells in vitro. However, canine guts were not dysbiotic in the presence of C. difficile. These findings support asymptomatic carriage in canines and, furthermore, suggest that there are features of the gut microbiome and/or a canine-specific immune response that may protect canines against CDI. We identified two biologically relevant bacteria that may aid in CDI resistance in canines: 1) Clostridium hiranonis, which synthesizes secondary bile acids that have been shown to provide resistance to CDI in mice; and 2) Sphingobacterium faecium, which produces sphingophospholipids that may be associated with regulating homeostasis in the canine gut. Our findings suggest that canines may be cryptic reservoirs for C. difficile and, furthermore, that mechanisms of CDI resistance in the canine gut could provide insights into targeted therapeutics for human CDI.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Asymptomatic carriage; Bile acid mediated resistance; Clostridioides difficile; Community-acquired infection; Microbial dysbiosis

Mesh:

Substances:

Year:  2019        PMID: 30946985     DOI: 10.1016/j.anaerobe.2019.03.017

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  8 in total

Review 1.  Akkermansia and Microbial Degradation of Mucus in Cats and Dogs: Implications to the Growing Worldwide Epidemic of Pet Obesity.

Authors:  Jose F Garcia-Mazcorro; Yasushi Minamoto; Jorge R Kawas; Jan S Suchodolski; Willem M de Vos
Journal:  Vet Sci       Date:  2020-04-15

2.  Gut microbiota features associated with Clostridioides difficile colonization in puppies.

Authors:  Alexander S F Berry; Brendan J Kelly; Denise Barnhart; Donna J Kelly; Daniel P Beiting; Robert N Baldassano; Laurel E Redding
Journal:  PLoS One       Date:  2019-08-30       Impact factor: 3.240

3.  A global to local genomics analysis of Clostridioides difficile ST1/RT027 identifies cryptic transmission events in a northern Arizona healthcare network.

Authors:  Charles H D Williamson; Nathan E Stone; Amalee E Nunnally; Heidie M Hornstra; David M Wagner; Chandler C Roe; Adam J Vazquez; Nivedita Nandurkar; Jacob Vinocur; Joel Terriquez; John Gillece; Jason Travis; Darrin Lemmer; Paul Keim; Jason W Sahl
Journal:  Microb Genom       Date:  2019-05-20

4.  Bacteremia Secondary to Uncommon Gram-Negative Bacilli Transmitted From the Canine in a Patient With Multiple Myeloma.

Authors:  Venu Madhav Konala; Srikanth Naramala; Subhashish Bose; Vijay Gayam; Bhaskar Reddy Madhira; Sreedhar Adapa
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

5.  Complete Genome Sequence of Peptacetobacter (Clostridium) hiranonis Strain DGF055142, Isolated from Dog Feces from Flagstaff, Arizona, USA, 2019.

Authors:  Nathan E Stone; Amalee E Nunnally; Chandler C Roe; Heidie M Hornstra; David M Wagner; Jason W Sahl
Journal:  Microbiol Resour Announc       Date:  2021-03-04

6.  Dogs as carriers of virulent and resistant genotypes of Clostridioides difficile.

Authors:  S K Finsterwalder; I Loncaric; A Cabal; M P Szostak; L M Barf; M Marz; F Allerberger; I A Burgener; A Tichy; A T Feßler; S Schwarz; S Monecke; R Ehricht; W Ruppitsch; J Spergser; F Künzel
Journal:  Zoonoses Public Health       Date:  2022-05-12       Impact factor: 2.954

7.  Effects of metronidazole on the fecal microbiome and metabolome in healthy dogs.

Authors:  Rachel Pilla; Frederic P Gaschen; James W Barr; Erin Olson; Julia Honneffer; Blake C Guard; Amanda B Blake; Dean Villanueva; Mohammad R Khattab; Mustafa K AlShawaqfeh; Jonathan A Lidbury; Jörg M Steiner; Jan S Suchodolski
Journal:  J Vet Intern Med       Date:  2020-08-28       Impact factor: 3.333

8.  The effect of combined carprofen and omeprazole administration on gastrointestinal permeability and inflammation in dogs.

Authors:  Susan M Jones; Ann Gaier; Hiroko Enomoto; Patricia Ishii; Rachel Pilla; Josh Price; Jan Suchodolski; Joerg M Steiner; Mark G Papich; Kristen Messenger; M Katherine Tolbert
Journal:  J Vet Intern Med       Date:  2020-09-07       Impact factor: 3.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.